Skip to Content

Join the 'Evolocumab' group to help and get support from people like you.

Evolocumab News

Coming Soon: Lower Cholesterol From a Twice-a-Year Shot?

Posted 15 Nov 2016 by Drugs.com

TUESDAY, Nov. 15, 2016 – Instead of popping a pill every day, people might soon control "bad" LDL cholesterol by getting an injection at their doctor's office two or three times a year. Researchers testing a new injectable drug called Inclisiran found it cut LDL cholesterol by half or more. According to early clinical trial data, the effect could last for four to six months. Inclisiran produced "significant and durable reductions in LDL cholesterol, and thus could potentially impact cardiovascular events," said study presenter Dr. Kausik Ray, a professor of public health at Imperial College London in England. Such long-lasting effects could provide a major advance in preventing heart disease, heart attack and stroke, by helping reduce hardening of the arteries, the researchers said. The trial results were presented Tuesday at the American Heart Association annual meeting in New ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Caduet, Repatha, Lescol, Hyperlipoproteinemia, Lescol XL

Are There Alternatives to Statins?

Posted 27 Sep 2016 by Drugs.com

TUESDAY, Sept. 27, 2016 – Statins are the go-to therapy for lowering "bad" LDL cholesterol, but other treatments also can effectively reduce risk of future heart problems, a new evidence review reports. These alternative therapies – including a heart-healthy diet, other cholesterol-lowering medications, and even intestinal bypass surgery – seem to confer the same level of heart health protection as statins when cholesterol levels decrease, according to the findings. Nonstatin therapies reduced the risk of heart problems by 25 percent for each 1 millimole per liter (mmol/L) decrease in LDL cholesterol levels. That's very similar to the 23 percent reduction per 1 mmol/L decrease seen with statins like atorvastatin (Lipitor) and simvastatin (Zocor), the researchers said. What's more, the benefits of these therapies stack up if more than one proves effective at lowering a person's ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Welchol, Zocor, Cholestyramine, Lovastatin, Zetia, Rosuvastatin, Vytorin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Gastric Bypass Surgery, Questran, Pravachol, Livalo, High Cholesterol - Familial Homozygous

FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor

Posted 1 Aug 2016 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose. Repatha is a human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9), which inhibits the body's natural system for eliminating "bad" cholesterol (low-density lipoprotein cholesterol or LDL-C) from the blood.1 Repatha is the first and only PCSK9 inhibitor to offer a monthly single-dose delivery option. Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge) "The Pushtronex system exemplifies Amgen's continued innovation and c ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Repatha, Evolocumab

Negative News on Statins Tied to Dropped Prescriptions

Posted 2 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 2, 2015 – News reports on the downsides of statins may push some people to stop taking the cholesterol-lowering drugs, a new study hints. The findings, published Dec. 2 in the European Heart Journal, cannot prove that media stories drive statin users to give up their prescriptions. Instead, Danish researchers found a broad correlation between "negative" media coverage and people's odds of quitting a statin within six months of their first prescription. But even without a clear cause-and-effect connection, experts said it's reasonable to assume that media stories had an influence over some statin users in the study. It rings true to Dr. Thomas Whayne Jr., of the Gill Heart Institute at the University of Kentucky. "I've seen this happen a lot," said Whayne, who was not involved in the study. "News stories come out, and you have patients saying, 'I'm not going to take ... Read more

Related support groups: Diabetes, Type 2, Muscle Pain, Heart Disease, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Zetia, Pre-Diabetes, Rosuvastatin, Vytorin, Hypertriglyceridemia, Pravachol, Livalo, Red Yeast Rice, Cardiovascular Risk Reduction

Heart Disease Doesn't Take a Holiday

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – People with heart disease should take a number of precautions if they travel over the Thanksgiving holiday, an expert suggests. The first step is to be as well-prepared on your trip as you are at home, said Dr. Winston Gandy Jr., a cardiologist at Piedmont Heart Institute in Atlanta. "Make sure when you travel that you have your medicine," Gandy said in an American Heart Association news release. Some people carry a copy of their original prescriptions in case they lose their medications, but having a list of your medications and your cardiologist's phone number should be sufficient. It's also a good idea to tell your cardiologist where you'll be. "Chances are your cardiologist is going to know someone there, either personally or by reputation," who can provide you with help if needed, Gandy said. Research medical facilities at your destination, and know what ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Niacin, Niaspan, Zocor, Azor, Lovastatin, Exforge, Benicar HCT, Diovan HCT, Hyzaar, Rosuvastatin, Lotrel, Avalide, Pravachol, Livalo, Hydrochlorothiazide/Lisinopril

FDA Approves Repatha for High Cholesterol

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among a new class called PCSK9 inhibitors, is sanctioned for people who are unable to reduce levels of the so-called LDL "bad" cholesterol with statin therapy and exercise, the agency said in a news release. Low-density lipoprotein, commonly known as LDL, builds up in the blood from natural and food sources, and is a leading cause of heart disease. About one in four deaths in the United States is linked to heart disease, making it the top cause of death among men and women. The condition kills about 610,000 people in the United States annually, the FDA said. Repatha is an antibody that targets the PCSK9 protein, which inhibits the liver's ability to remove LDL from the blood. Its most ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha - Second Drug in New Class of Cholesterol-Lowering Medications

Posted 31 Aug 2015 by Drugs.com

THURSDAY, Aug. 27, 2015 – The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol. Repatha (evolocumab), an injectable drug, works by blocking a protein that interferes with the liver's ability to remove LDL cholesterol from the blood. In July, the FDA approved Praluent (alirocumab), another injectable drug in the same class of medications as Repatha. Both drugs are called PCSK9 inhibitors, which don't seem to cause the muscle problems that cholesterol-lowering statin drugs sometimes can. "Repatha provides another treatment option in this new class of drugs for patients with familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough with statins," said Dr. John Jenkins, director of the FDA's Office of New ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol

Posted 31 Aug 2015 by Drugs.com

August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Familial hypercholesterolemia (encompassing both HeFH and HoFH) is an inherited condition that causes high levels of LDL cholesterol. A high level of LDL cholesterol in the blood is linked to cardiovascular or heart disease. Heart ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, High Cholesterol

Related Drug Support Groups

Repatha, Repatha Pushtronex

Evolocumab Patient Information at Drugs.com